ALK and non-small cell lung carcinoma: Consistent with its broad ALK mutation coverage and CNS penetration, loratinib showed significant overall and intracranial activity ALK tyrosine kinase inhibitor in both ALK-positive NSCLC primary patients and in crizotinib second-generation therapy [41].